Study identifier:D6997L00004
ClinicalTrials.gov identifier:NCT00327769
EudraCT identifier:N/A
CTIS identifier:N/A
A double blind, double dummy, randomised, multicentre study to compare the efficacy and safety of Fulvestrant 250mg with Arimidex 1mg as a secondary-line therapy in the postmenopausal women with oestrogen receptor positive advanced breast cancer
Advanced breast cancer
Phase 3
No
Fulvestrant, Anastrozole
Female
234
Interventional
18 Years +
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Feb 2025 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
This study will evaluate the efficacy and safety of Faslodex as secondary-line treatment compared with Arimidex in oestrogen receptor positive postmenopausal advanced breast cancer.
Arms | Assigned Interventions |
---|---|
Active Comparator: 1 Anastrozole | Drug: Anastrozole 1 mg tablet Other Name: Arimidex Other Name: ZD1033 |
Experimental: 2 Anastrozole + Fulvestrant | Drug: Fulvestrant 250 mg intramuscular injection Other Name: Faslodex Other Name: ZD9238 Drug: Anastrozole 1 mg tablet Other Name: Arimidex Other Name: ZD1033 |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.